Skip to content

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05064787
Enrollment
45
Registered
2021-10-01
Start date
2022-03-11
Completion date
2024-02-06
Last updated
2024-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma, Leukemia, Leukemia, Acute Lymphoblastic, Lymphoma, Lymphoma, B-Cell, Mantle Cell Lymphoma, Multiple Myeloma

Keywords

Receptors, chimeric antigen, Adult, hematologic neoplasms, digital health coaching

Brief summary

The aim of this study is to evaluate the feasibility of a digital health coaching program for, and to describe quality of life of, individuals in the 6 months following chimeric antigen receptor (CAR) T cell therapy. Up to 50 English-speaking individuals aged 18 and older who are to receive treatment with a CAR T cell therapy will be enrolled, all at The University of Texas MD Anderson Cancer Center. Participants must have internet access via smart phone, tablet, a computer, or another device with the capacity to receive calls, texts, or e-mails, as well as the electronic study assessments and will be excluded if they are unable to provide informed consent or have a prognosis of 6 months or less. Consented participants will be enrolled in a 6-month digital health coaching program delivered via weekly calls from a Health Advisor coupled with the digital delivery of content. The program focuses on identification and escalation of treatment-related toxicity, communication with providers, and physical and psychosocial health following treatment. Health related quality of life (HRQoL) will be assessed with the Functional Assessment of Cancer Therapy-Lymphoma (FACT-L), health self-efficacy will be assessed by the Cancer Behavior Inventory-Brief (CBI-B), physical and mental health outcomes will be measured by the National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) Global Health 10. Patient experience in managing CAR T specific care will be assessed with a 5-item questionnaire developed specifically for use in this study, focused on participants' confidence in understanding, identifying and managing symptoms, and communicating with providers. Study outcomes will contribute to knowledge about if and how a digital health intervention may be used to support individuals post-CAR T cell therapy.

Interventions

The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.

Sponsors

M.D. Anderson Cancer Center
CollaboratorOTHER
Bristol-Myers Squibb
CollaboratorINDUSTRY
Pack Health
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

A single cohort of 50 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of which will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled from a single site, The University of Texas MD Anderson Cancer Center.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 and older * Able to read, speak and consent in English * Confirmed treatment with any commercially available or investigational CAR T cell therapy. * Internet access via smart phone, tablet, a computer, or another device with the capacity to receive calls, texts, or e-mails, as well as the electronic study assessments. * Ability to engage in physical activity as evidenced by an Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 2

Exclusion criteria

* Individuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment) * Individuals for whom there is documentation of inability to provide consent in the medical record. * Non-English speaking/reading individuals.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the interventionThrough study completion, at month 6Feasibility is defined as a retention rate in the digital health coaching program greater than or equal to 60% at month 6
AcceptabilityThrough study completion, at month 6Acceptability will be assessed with a 3-item evaluation to address engagement, usefulness and relevance

Secondary

MeasureTime frameDescription
Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)Enrollment, Months 1, 3, 6The FACT-lym is a 42-item assessment that measures self-reported quality of life across 4 domains: physical, functional, emotional and social and includes 15 additional items validated specifically for individuals with lymphoma. The instrument can be scored as a whole as well as within the individual domains.
Cancer Behavior Inventory (CBI-B)Enrollment, Months 1, 3, 6This 12-item instrument measures self-efficacy in coping with cancer across 7 domains. These include: Seeking and Understanding Medical Information, Emotion Regulation, Coping with Treatment Related Side Effects, Accepting Cancer/ Maintaining a Positive Attitude, Seeking Social Support, and Using Spiritual Coping. The instrument utilizes a 9-point response scale ranging from 1 Not at all confident to 9 Confident.
National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) Global Health 10Enrollment, Month 6Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale is a ten item likert-scale survey that evaluates physical, social, and psychological well-being. The instrument consists of two scales, one for global physical health and one for global mental health.
Subjective Assessment of CAR T ManagementEnrollment, Months 1, 3, 6a 5-item assessment of patients' experience in monitoring, managing, and reporting treatment related toxicities will be created specifically for use in this study and will mirror the response scale in the CBI-B. This includes a 9-point response scale ranging from 1 Not at all confident to 9 Confident. The following items will be included: 1) Understand the treatment toxicities I may experience while receiving CAR T-cell therapy; 2) Identify the signs and symptoms of these toxicities; 3) Communicate symptoms to provider; 4) Manage symptoms according to provider's instructions; 5) Explain treatment to a healthcare provider.

Other

MeasureTime frameDescription
Health Care UtilizationThrough study completion, at month 6ER visits and unplanned hospitalizations
Socio-demographic, clinical, and treatment characteristicsThrough study completion, at month 6Age, Race, Ethnicity, Sex at Birth, Gender Identity, Diagnosis, Treatment History, Co-morbid conditions
Digital EngagementThrough study completion, at month 6Frequency, types and duration of engagement with the digital health coaching platform

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026